COMPANY
March Biosciences
Funding and NIH signals
- NIH award NIH awarded $399K (SBIR Phase II 1R44CA314963-01, new, notice Sep 17, 2026); 2 NIH awards totaling $1.52M in the last 12 months. NIH RePORTER 1R44CA314963-01 (Sep 17, 2026)
Evidence (2 events)
- Sep 17, 2026 · NIH RePORTER 1R44CA314963-01
Organization: MARCH BIOSCIENCES INC; City/State: HOUSTON, TX; Project number: 1R44CA314963-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 399003; Administering IC: National Cancer Institute; Project title: Overcoming Immune Evasion in Hepatocellular Carcinoma with Engineered T-Cell Therapy; Organization type: Domestic For-Profits - Aug 31, 2026 · NIH RePORTER 5R44CA302357-02
Organization: MARCH BIOSCIENCES INC; City/State: HOUSTON, TX; Project number: 5R44CA302357-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-31; FY total cost (award amount): 1124607; Administering IC: National Cancer Institute; Project title: A Phase 2 multi-center trial of CD5 CAR T-cell therapy in patients with T-cell lymphoma; Organization type: Domestic For-Profits
- Sep 17, 2026 · NIH RePORTER 1R44CA314963-01
Timeline
- Trial start —: A Long-term Follow-up Study of Patients Who Received MB-105 source ↗
- Trial start Phase 2: MB-105 in Patients With CD5 Positive T-cell Lymphoma source ↗
- Raise Private equity round — Series A: $28.4M (total, as published), announced Oct 23, 2024. Source: company release on GlobeNewswire. source ↗
Upcoming milestones
- 2028-02 (ESTIMATED) · Phase 2 · MB-105 in Patients With CD5 Positive T-cell Lymphoma · NCT06534060
- Oct 15, 2040 (ESTIMATED) · · A Long-term Follow-up Study of Patients Who Received MB-105 · NCT07340814
Funding
- Private equity round — Series A: $28.4M (total, as published), announced Oct 23, 2024. Source: company release on GlobeNewswire. source ↗
Clinical trials (lead sponsor) 2
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT07340814 | A Long-term Follow-up Study of Patients Who Received MB-105 | Not listed | Not yet recruiting | Feb 27, 2026 | Oct 15, 2040 (estimated) |
| NCT06534060 | MB-105 in Patients With CD5 Positive T-cell Lymphoma | Phase 2 | Recruiting | Feb 15, 2025 | 2028-02 (estimated) |
NIH awards 5
- NIH award 1R44CA314963-01 FY2026: $399,003 awarded for that fiscal year; activity R44 (SBIR); PI SMITH, ERIC ANDREW; recipient as written: MARCH BIOSCIENCES INC, HOUSTON, TX. Overcoming Immune Evasion in Hepatocellul source ↗
- NIH award 5R44CA302357-02 FY2026: $1,124,607 awarded for that fiscal year; activity R44 (SBIR); PI HEIN, SARAH MARIE; recipient as written: MARCH BIOSCIENCES INC, HOUSTON, TX. A Phase 2 multi-center trial of CD5 CAR source ↗
- NIH award 5R44CA295245-02 FY2025: $986,080 awarded for that fiscal year; activity R44 (SBIR); PI HEIN, SARAH MARIE; recipient as written: MARCH BIOSCIENCES INC, HOUSTON, TX. Dual-targeting allogeneic CAR T-cells for source ↗
- NIH award 1R44CA302357-01 FY2025: $1,124,607 awarded for that fiscal year; activity R44 (SBIR); PI HEIN, SARAH MARIE; recipient as written: MARCH BIOSCIENCES INC, HOUSTON, TX. A Phase 2 multi-center trial of CD5 CAR source ↗
- NIH award 1R44CA295245-01 FY2024: $1,013,623 awarded for that fiscal year; activity R44 (SBIR); PI HEIN, SARAH MARIE; recipient as written: MARCH BIOSCIENCES INC, HOUSTON, TX. Dual-targeting allogeneic CAR T-cells fo source ↗